{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T02:05:08Z","timestamp":1793239508002,"version":"4.5.0"},"reference-count":73,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"1","license":[{"start":{"date-parts":[[2025,8,27]],"date-time":"2025-08-27T00:00:00Z","timestamp":1756252800000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-sa\/4.0\/"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,1]]},"abstract":"<jats:sec>\n                    <jats:title>Background:<\/jats:title>\n                    <jats:p>Anaplastic thyroid carcinoma (ATC) is a rare, aggressive solid tumor with poor prognosis. Traditional treatment such as surgery, radiotherapy, and chemotherapy has limited therapeutic effects. In recent years, immunotherapy is changing the treatment pattern of them. We systematically summarize the research status and application of immunotherapy in ATC to provide clinicians and relevant researchers with a comprehensive perspective.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Method:<\/jats:title>\n                    <jats:p>A comprehensive search of the PubMed and Embase databases identified 18 studies investigating the application of immunotherapy in ATC. These included ten cohort studies and eight case reports. The quality of the included studies was assessed using the Newcastle-Ottawa Quality Assessment Scale (NOS) and Joanna Briggs Institute checklist (JBI). Subsequently, a single-proportion meta-analysis and meta-regression were performed to evaluate the efficacy of immunotherapy in ATC.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>\n                      The favorable response rate to immunotherapy in ATC patients (33\u2013100%) varies across cohorts, indicating substantial heterogeneity. The combination of immunotherapy with targeted therapy, as well as the use of neoadjuvant treatment, has led to improved outcomes for ATC. Single-proportion meta-analysis suggests that immunotherapy may provide clinical benefits for a subset of ATC patients (approximately one-third to one-half), but its effectiveness in controlling disease progression remains limited. Meta-regression further indicates that ATC patients with PD-L1 expression or BRAF\n                      <jats:sup>V600E<\/jats:sup>\n                      mutations tend to have better treatment responses. Among the 8 case reports, two patients achieved complete remission after immunotherapy, and four patients died of disease progression after immunotherapy. Mild adverse effects are common, but interstitial pneumonia is associated with poor prognosis in immunotherapy.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion:<\/jats:title>\n                    <jats:p>\n                      Immunotherapy for ATC has demonstrated safety and efficacy in several studies, especially in patients with PD-L1 expression or BRAF\n                      <jats:sup>V600E<\/jats:sup>\n                      mutations. However, immune-related side effects should be carefully managed, particularly to prevent interstitial pneumonia.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1097\/js9.0000000000003301","type":"journal-article","created":{"date-parts":[[2025,8,28]],"date-time":"2025-08-28T00:00:29Z","timestamp":1756339229000},"page":"1708-1721","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":2,"title":["Efficacy and safety of immunotherapy in anaplastic thyroid carcinoma: a systematic review and meta-analysis"],"prefix":"10.1097","volume":"112","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5628-8555","authenticated-orcid":false,"given":"Kang","family":"Ning","sequence":"first","affiliation":[{"name":"Department of Head and Neck Surgery, Sun Yat-sen University Cancer Center, Guangzhou, China"},{"name":"State Key Laboratory of Oncology in Southern China, Collaborative Innovation Center for Cancer Medicine, Guangzhou, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qiaorong","family":"Chen","sequence":"additional","affiliation":[{"name":"Zhongshan School of Medicine, Sun Yat-sen University, Guangzhou, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu","family":"Guo","sequence":"additional","affiliation":[{"name":"Department of Thyroid Center\/Thyroid Surgery, The Sixth Affiliated Hospital, Sun Yat-sen University, Guangzhou, China"},{"name":"Department of Otorhinolaryngology Head and Neck Surgery, The Sixth Affiliated Hospital, Sun Yat-sen University, Guangzhou, China"},{"name":"Department of Thyroid Surgery, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hao","family":"Li","sequence":"additional","affiliation":[{"name":"The Second Clinical College of Hainan Medical University, Haikou, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bu","family":"Zou","sequence":"additional","affiliation":[{"name":"Department of Head and Neck Surgery, Sun Yat-sen University Cancer Center, Guangzhou, China"},{"name":"State Key Laboratory of Oncology in Southern China, Collaborative Innovation Center for Cancer Medicine, Guangzhou, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Taonong","family":"Cai","sequence":"additional","affiliation":[{"name":"Department of Head and Neck Surgery, Sun Yat-sen University Cancer Center, Guangzhou, China"},{"name":"State Key Laboratory of Oncology in Southern China, Collaborative Innovation Center for Cancer Medicine, Guangzhou, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li","family":"Wang","sequence":"additional","affiliation":[{"name":"State Key Laboratory of Oncology in Southern China, Collaborative Innovation Center for Cancer Medicine, Guangzhou, China"},{"name":"Department of Medical Oncology, Sun Yat-sen University Cancer Center, Guangzhou, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yongchao","family":"Yu","sequence":"additional","affiliation":[{"name":"Department of Head and Neck Surgery, Sun Yat-sen University Cancer Center, Guangzhou, China"},{"name":"State Key Laboratory of Oncology in Southern China, Collaborative Innovation Center for Cancer Medicine, Guangzhou, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhenyu","family":"Luo","sequence":"additional","affiliation":[{"name":"Department of Head and Neck Surgery, Sun Yat-sen University Cancer Center, Guangzhou, China"},{"name":"State Key Laboratory of Oncology in Southern China, Collaborative Innovation Center for Cancer Medicine, Guangzhou, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jian","family":"Bu","sequence":"additional","affiliation":[{"name":"Zhongshan School of Medicine, Sun Yat-sen University, Guangzhou, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Han","family":"Hong","sequence":"additional","affiliation":[{"name":"Zhongshan School of Medicine, Sun Yat-sen University, Guangzhou, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ziying","family":"Li","sequence":"additional","affiliation":[{"name":"School of Medicine, Shenzhen Campus of Sun Yat-sen University, Sun Yat-sen University, Shenzhen, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xujia","family":"Wen","sequence":"additional","affiliation":[{"name":"Zhongshan School of Medicine, Sun Yat-sen University, Guangzhou, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mingjie","family":"Jiang","sequence":"additional","affiliation":[{"name":"Department of Head and Neck Surgery, Sun Yat-sen University Cancer Center, Guangzhou, China"},{"name":"State Key Laboratory of Oncology in Southern China, Collaborative Innovation Center for Cancer Medicine, Guangzhou, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tong","family":"Wu","sequence":"additional","affiliation":[{"name":"Department of Head and Neck Surgery, Sun Yat-sen University Cancer Center, Guangzhou, China"},{"name":"State Key Laboratory of Oncology in Southern China, Collaborative Innovation Center for Cancer Medicine, Guangzhou, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tianrun","family":"Liu","sequence":"additional","affiliation":[{"name":"Department of Thyroid Surgery, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weichao","family":"Chen","sequence":"additional","affiliation":[{"name":"Department of Head and Neck Surgery, Sun Yat-sen University Cancer Center, Guangzhou, China"},{"name":"State Key Laboratory of Oncology in Southern China, Collaborative Innovation Center for Cancer Medicine, Guangzhou, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zan","family":"Jiao","sequence":"additional","affiliation":[{"name":"Department of Head and Neck Surgery, Sun Yat-sen University Cancer Center, Guangzhou, China"},{"name":"State Key Laboratory of Oncology in Southern China, Collaborative Innovation Center for Cancer Medicine, Guangzhou, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ankui","family":"Yang","sequence":"additional","affiliation":[{"name":"Department of Head and Neck Surgery, Sun Yat-sen University Cancer Center, Guangzhou, China"},{"name":"State Key Laboratory of Oncology in Southern China, Collaborative Innovation Center for Cancer Medicine, Guangzhou, China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2025,8,27]]},"reference":[{"key":"R1-20260518","first-page":"100082","article-title":"Transparency In The reporting of Artificial INtelligence \u2013 the TITAN guideline","volume":"10","author":"Agha","year":"2025","journal-title":"Prem J Sci"},{"key":"R2-20260518","doi-asserted-by":"crossref","first-page":"1531\u201344","DOI":"10.1016\/S0140-6736(23)00020-X","article-title":"Thyroid cancer","volume":"401","author":"Chen","year":"2023","journal-title":"Lancet"},{"key":"R3-20260518","doi-asserted-by":"crossref","first-page":"337\u201386","DOI":"10.1089\/thy.2020.0944","article-title":"2021 American Thyroid Association guidelines for management of patients with anaplastic thyroid cancer","volume":"31","author":"Bible","year":"2021","journal-title":"Thyroid"},{"key":"R4-20260518","doi-asserted-by":"crossref","first-page":"644\u201360","DOI":"10.1038\/nrendo.2017.76","article-title":"Anaplastic thyroid carcinoma: from clinicopathology to genetics and advanced therapies","volume":"13","author":"Molinaro","year":"2017","journal-title":"Nat Rev Endocrinol"},{"key":"R5-20260518","doi-asserted-by":"crossref","first-page":"672\u201381","DOI":"10.1089\/thy.2016.0395","article-title":"Patterns of treatment failure in anaplastic thyroid carcinoma","volume":"27","author":"Rao","year":"2017","journal-title":"Thyroid"},{"key":"R6-20260518","doi-asserted-by":"crossref","first-page":"7\u201313","DOI":"10.1200\/JCO.2017.73.6785","article-title":"Dabrafenib and trametinib treatment in patients with locally advanced or metastatic BRAF v600-mutant anaplastic thyroid cancer","volume":"36","author":"Subbiah","year":"2018","journal-title":"J Clin Oncol"},{"key":"R7-20260518","doi-asserted-by":"crossref","first-page":"179","DOI":"10.3390\/cancers15010179","article-title":"Targeted therapy for anaplastic thyroid carcinoma: advances and management","volume":"15","author":"Yuan","year":"2022","journal-title":"Cancers"},{"key":"R8-20260518","doi-asserted-by":"crossref","first-page":"5205","DOI":"10.3390\/cancers14215205","article-title":"Role of immunotherapy in the treatment of cancer: a systematic review","volume":"14","author":"Ling","year":"2022","journal-title":"Cancers"},{"key":"R9-20260518","doi-asserted-by":"crossref","first-page":"113365","DOI":"10.1016\/j.intimp.2024.113365","article-title":"A comprehensive review of immune checkpoint inhibitors for cancer treatment","volume":"143","author":"Arafat Hossain","year":"2024","journal-title":"Int Immunopharmacol"},{"key":"R10-20260518","doi-asserted-by":"crossref","first-page":"807\u201321","DOI":"10.1038\/s41423-020-0488-6","article-title":"The history and advances in cancer immunotherapy: understanding the characteristics of tumor-infiltrating immune cells and their therapeutic implications","volume":"17","author":"Zhang","year":"2020","journal-title":"Cell Mol Immunol"},{"key":"R11-20260518","doi-asserted-by":"crossref","first-page":"491\u201398","DOI":"10.1016\/j.semcancer.2022.03.020","article-title":"The evolutionary legacy of immune checkpoint inhibitors","volume":"86","author":"Kaushik","year":"2022","journal-title":"Semin Cancer Biol"},{"key":"R12-20260518","doi-asserted-by":"crossref","first-page":"e2","DOI":"10.4110\/in.2022.22.e2","article-title":"Immune checkpoint inhibitors in 10 years: contribution of basic research and clinical application in cancer immunotherapy","volume":"22","author":"Lee","year":"2022","journal-title":"Immune Netw"},{"key":"R13-20260518","doi-asserted-by":"crossref","first-page":"480\u201389","DOI":"10.1038\/nature10673","article-title":"Cancer immunotherapy comes of age","volume":"480","author":"Mellman","year":"2011","journal-title":"Nature"},{"key":"R14-20260518","first-page":"100041","article-title":"Current status and future perspective of immunotherapy in gastrointestinal cancers","volume":"1","author":"Lu","year":"2020","journal-title":"Innovation (Camb)"},{"key":"R15-20260518","doi-asserted-by":"crossref","first-page":"512\u201333","DOI":"10.1007\/s11427-020-1768-y","article-title":"Current status and future perspectives of immunotherapy in bladder cancer treatment","volume":"64","author":"Wu","year":"2021","journal-title":"Sci China Life Sci"},{"key":"R16-20260518","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1186\/s12943-023-01740-y","article-title":"Lung cancer immunotherapy: progress, pitfalls, and promises","volume":"22","author":"Lahiri","year":"2023","journal-title":"Mol Cancer"},{"key":"R17-20260518","doi-asserted-by":"crossref","first-page":"525\u201343","DOI":"10.1038\/s41575-021-00438-0","article-title":"Advances in immunotherapy for hepatocellular carcinoma","volume":"18","author":"Sangro","year":"2021","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"R18-20260518","doi-asserted-by":"crossref","first-page":"e2301975","DOI":"10.1002\/advs.202301975","article-title":"Targeting alpha-ketoglutarate disruption overcomes immunoevasion and improves PD-1 blockade immunotherapy in renal cell carcinoma","volume":"10","author":"Li","year":"2023","journal-title":"Adv Sci (Weinh)"},{"key":"R19-20260518","first-page":"397\u2013404","article-title":"Pembrolizumab monotherapy for previously treated metastatic triple-negative breast cancer: cohort A of the phase II KEYNOTE-086 study","volume":"30","author":"Adams","year":"2019","journal-title":"Ann Oncol"},{"key":"R20-20260518","doi-asserted-by":"crossref","first-page":"S748","DOI":"10.1016\/S1556-0864(21)01939-0","article-title":"97O First-line pembrolizumab plus chemotherapy for patients with advanced squamous NSCLC: 3-year follow-up from KEYNOTE-407","volume":"16","author":"Robinson","year":"2021","journal-title":"J Thorac Oncol"},{"key":"R21-20260518","doi-asserted-by":"crossref","first-page":"586\u201397","DOI":"10.1200\/JCO.21.01497","article-title":"First-line immunotherapy for non-small-cell lung cancer","volume":"40","author":"Reck","year":"2022","journal-title":"J Clin Oncol"},{"key":"R22-20260518","doi-asserted-by":"crossref","first-page":"61\u201367","DOI":"10.1089\/thy.2020.0312","article-title":"Immune profiling of advanced thyroid cancers using fluorescent multiplex immunohistochemistry","volume":"31","author":"Ahn","year":"2021","journal-title":"Thyroid"},{"key":"R23-20260518","doi-asserted-by":"crossref","first-page":"1575\u201384","DOI":"10.1158\/1535-7163.MCT-17-0871","article-title":"Molecular profile of advanced thyroid carcinomas by next-generation sequencing: characterizing tumors beyond diagnosis for targeted therapy","volume":"17","author":"Chen","year":"2018","journal-title":"Mol Cancer Ther"},{"key":"R24-20260518","doi-asserted-by":"crossref","first-page":"17194\u2013211","DOI":"10.18632\/oncotarget.7839","article-title":"Combining BRAF inhibitor and anti PD-L1 antibody dramatically improves tumor regression and anti tumor immunity in an immunocompetent murine model of anaplastic thyroid cancer","volume":"7","author":"Brauner","year":"2016","journal-title":"Oncotarget"},{"key":"R25-20260518","doi-asserted-by":"crossref","first-page":"1195\u2013204","DOI":"10.1002\/cncr.34657","article-title":"Efficacy and safety of pembrolizumab monotherapy in patients with advanced thyroid cancer in the phase 2 KEYNOTE-158 study","volume":"129","author":"Oh","year":"2023","journal-title":"Cancer"},{"key":"R26-20260518","doi-asserted-by":"crossref","first-page":"336\u201346","DOI":"10.1089\/thy.2023.0573","article-title":"Checkpoint inhibition in addition to dabrafenib\/trametinib for BRAF(v600e)-mutated anaplastic thyroid carcinoma","volume":"34","author":"Hamidi","year":"2024","journal-title":"Thyroid"},{"key":"R27-20260518","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1186\/s12885-019-5380-3","article-title":"Safety and antitumor activity of the anti-PD-1 antibody pembrolizumab in patients with advanced, PD-L1-positive papillary or follicular thyroid cancer","volume":"19","author":"Mehnert","year":"2019","journal-title":"BMC Cancer"},{"key":"R28-20260518","doi-asserted-by":"crossref","first-page":"1615\u201322","DOI":"10.1089\/thy.2019.0086","article-title":"A phase 2 study of pembrolizumab combined with chemoradiotherapy as initial treatment for anaplastic thyroid cancer","volume":"29","author":"Chintakuntlawar","year":"2019","journal-title":"Thyroid"},{"key":"R29-20260518","doi-asserted-by":"crossref","first-page":"n71","DOI":"10.1136\/bmj.n71","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","author":"Page","year":"2021","journal-title":"Bmj"},{"key":"R30-20260518","doi-asserted-by":"crossref","first-page":"j4008","DOI":"10.1136\/bmj.j4008","article-title":"AMSTAR 2: a critical appraisal tool for systematic reviews that include randomised or non-randomised studies of healthcare interventions, or both","volume":"358","author":"Shea","year":"2017","journal-title":"Bmj"},{"key":"R31-20260518","doi-asserted-by":"crossref","first-page":"e0147601","DOI":"10.1371\/journal.pone.0147601","article-title":"Panethnic differences in blood pressure in Europe: a systematic review and meta-analysis","volume":"11","author":"Modesti","year":"2016","journal-title":"PLoS One"},{"key":"R32-20260518","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1186\/s12957-021-02432-x","article-title":"The efficacy of ileostomy after laparoscopic rectal cancer surgery: a meta-analysis","volume":"19","author":"Mu","year":"2021","journal-title":"World J Surg Oncol"},{"key":"R33-20260518","doi-asserted-by":"crossref","first-page":"603\u201305","DOI":"10.1007\/s10654-010-9491-z","article-title":"Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses","volume":"25","author":"Stang","year":"2010","journal-title":"Eur J Epidemiol"},{"key":"R34-20260518","doi-asserted-by":"crossref","first-page":"d5928","DOI":"10.1136\/bmj.d5928","article-title":"The Cochrane collaboration\u2019s tool for assessing risk of bias in randomised trials","volume":"343","author":"Higgins","year":"2011","journal-title":"Bmj"},{"key":"R35-20260518","first-page":"217","article-title":"Chapter 7: systematic reviews of etiology and risk. In: Aromataris E, Munn Z (editors)","volume":"1","author":"Moola","year":"2020","journal-title":"JBI Evid Synth"},{"key":"R36-20260518","first-page":"Ed000142","article-title":"Updated guidance for trusted systematic reviews: a new edition of the Cochrane handbook for systematic reviews of interventions","volume":"10","author":"Cumpston","year":"2019","journal-title":"Cochrane Database Syst Rev"},{"key":"R37-20260518","doi-asserted-by":"crossref","first-page":"70\u201386","DOI":"10.1016\/j.critrevonc.2019.04.003","article-title":"Dietary total antioxidant capacity and risk of cancer: a systematic review and meta-analysis on observational studies","volume":"138","author":"Parohan","year":"2019","journal-title":"Crit Rev Oncol Hematol"},{"key":"R38-20260518","doi-asserted-by":"crossref","first-page":"676\u201380","DOI":"10.1001\/jama.295.6.676","article-title":"Comparison of two methods to detect publication bias in meta-analysis","volume":"295","author":"Peters","year":"2006","journal-title":"Jama"},{"key":"R39-20260518","doi-asserted-by":"crossref","first-page":"1663\u20131671","DOI":"10.1001\/jamaoncol.2024.4019","article-title":"Dual immune checkpoint inhibition in patients with aggressive thyroid carcinoma","volume":"10","author":"Sehgal","year":"2024","journal-title":"JAMA Oncol"},{"key":"R40-20260518","doi-asserted-by":"crossref","first-page":"926\u201336","DOI":"10.1089\/thy.2022.0073","article-title":"An evaluation of clinical efficacy of immune checkpoint inhibitors for patients with anaplastic thyroid carcinoma","volume":"32","author":"Hatashima","year":"2022","journal-title":"Thyroid"},{"key":"R41-20260518","doi-asserted-by":"crossref","first-page":"e005225","DOI":"10.1136\/jitc-2022-005225","article-title":"Durable response of anaplastic thyroid carcinoma to FS118, a bispecific LAG-3\/PD-L1 antibody, after checkpoint inhibitor progression: a case report","volume":"10","author":"Kroloff","year":"2022","journal-title":"J Immunotherap Cancer"},{"key":"R42-20260518","doi-asserted-by":"crossref","first-page":"1149\u201351","DOI":"10.1634\/theoncologist.2017-0096","article-title":"Exceptional response with immunotherapy in a patient with anaplastic thyroid cancer","volume":"22","author":"Kollipara","year":"2017","journal-title":"Oncologist"},{"key":"R43-20260518","doi-asserted-by":"crossref","first-page":"945\u201351","DOI":"10.1089\/thy.2018.0060","article-title":"Neoadjuvant BRAF- and immune-directed therapy for anaplastic thyroid carcinoma","volume":"28","author":"Cabanillas","year":"2018","journal-title":"Thyroid"},{"key":"R44-20260518","doi-asserted-by":"crossref","first-page":"734\u201342","DOI":"10.1111\/cen.14679","article-title":"Mutation based approaches to the treatment of anaplastic thyroid cancer","volume":"96","author":"McCrary","year":"2022","journal-title":"Clin Endocrinol"},{"key":"R45-20260518","doi-asserted-by":"crossref","first-page":"1672","DOI":"10.1001\/jamaoncol.2024.4729","article-title":"Anti\u2013programmed death ligand 1 plus targeted therapy in anaplastic thyroid carcinoma","volume":"10","author":"Cabanillas","year":"2024","journal-title":"JAMA Oncol"},{"key":"R46-20260518","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1186\/s40425-018-0378-y","article-title":"Salvage pembrolizumab added to kinase inhibitor therapy for the treatment of anaplastic thyroid carcinoma","volume":"6","author":"Iyer","year":"2018","journal-title":"J Immunotherap Cancer"},{"key":"R47-20260518","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1186\/s12902-024-01555-y","article-title":"First effectiveness data of lenvatinib and pembrolizumab as first-line therapy in advanced anaplastic thyroid cancer: a retrospective cohort study","volume":"24","author":"Soll","year":"2024","journal-title":"BMC Endocr Disord"},{"key":"R48-20260518","doi-asserted-by":"crossref","first-page":"2620\u201327","DOI":"10.1200\/JCO.19.02727","article-title":"PD-1 Blockade in Anaplastic Thyroid Carcinoma","volume":"38","author":"Capdevila","year":"2020","journal-title":"J Clin Oncol"},{"key":"R49-20260518","doi-asserted-by":"crossref","first-page":"1389294","DOI":"10.3389\/fendo.2024.1389294","article-title":"Neoadjuvant treatment with lenvatinib and pembrolizumab in a BRAF V600E-mutated anaplastic thyroid cancer: a case report","volume":"15","author":"Barbaro","year":"2024","journal-title":"Front Endocrinol"},{"key":"R50-20260518","doi-asserted-by":"crossref","first-page":"5401\u201307","DOI":"10.3390\/curroncol28060450","article-title":"Combination of lenvatinib and pembrolizumab as salvage treatment for paucicellular variant of anaplastic thyroid cancer: a case report","volume":"28","author":"Luongo","year":"2021","journal-title":"Current Oncol"},{"key":"R51-20260518","doi-asserted-by":"crossref","first-page":"107067","DOI":"10.1016\/j.oraloncology.2024.107067","article-title":"Combination kinase inhibitors and immunotherapy for unresectable anaplastic thyroid carcinoma: a retrospective single-center study","volume":"159","author":"Song","year":"2024","journal-title":"Oral Oncol"},{"key":"R52-20260518","doi-asserted-by":"crossref","first-page":"1013\u201320","DOI":"10.1007\/s12020-023-03647-6","article-title":"The role of targeted therapy and\/or immunotherapy therapy in anaplastic thyroid carcinoma","volume":"84","author":"Wu","year":"2023","journal-title":"Endocrine"},{"key":"R53-20260518","first-page":"1167\u201373","article-title":"Immunotherapy in anaplastic thyroid cancer: case series","volume":"121","author":"Shih","year":"2022","journal-title":"JFormos Med Assoc"},{"key":"R54-20260518","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1530\/ETJ-23-0144","article-title":"Combinatorial hypofractionated radiotherapy and pembrolizumab in anaplastic thyroid cancer","volume":"13","author":"Tan","year":"2024","journal-title":"Eur Thyroid J"},{"key":"R55-20260518","doi-asserted-by":"crossref","first-page":"3849\u201355","DOI":"10.12998\/wjcc.v10.i12.3849","article-title":"Combined targeted therapy and immunotherapy in anaplastic thyroid carcinoma with distant metastasis: a case report","volume":"10","author":"Ma","year":"2022","journal-title":"World J Clin Cases"},{"key":"R56-20260518","doi-asserted-by":"crossref","first-page":"1076\u201385","DOI":"10.1089\/thy.2020.0322","article-title":"Combination of lenvatinib and pembrolizumab is an effective treatment option for anaplastic and poorly differentiated thyroid carcinoma","volume":"31","author":"Dierks","year":"2021","journal-title":"Thyroid"},{"key":"R57-20260518","doi-asserted-by":"crossref","first-page":"712107","DOI":"10.3389\/fendo.2021.712107","article-title":"FGF-receptors and PD-l1 in anaplastic and poorly differentiated thyroid cancer: evaluation of the preclinical rationale","volume":"12","author":"Adam","year":"2021","journal-title":"Front Endocrinol"},{"key":"R58-20260518","doi-asserted-by":"crossref","first-page":"81\u201394","DOI":"10.1038\/nrclinonc.2017.166","article-title":"Tumour heterogeneity and resistance to cancer therapies","volume":"15","author":"Dagogo-Jack","year":"2018","journal-title":"Nat Rev Clin Oncol"},{"key":"R59-20260518","doi-asserted-by":"crossref","first-page":"2367\u201373","DOI":"10.1158\/1078-0432.CCR-16-2154-T","article-title":"Genomic heterogeneity and exceptional response to dual pathway inhibition in anaplastic thyroid cancer","volume":"23","author":"Gibson","year":"2017","journal-title":"Clin Cancer Res"},{"key":"R60-20260518","first-page":"e173712","article-title":"A distinct tumor microenvironment makes anaplastic thyroid cancer more lethal but immunotherapy sensitive than papillary thyroid cancer","volume":"9","author":"Han","year":"2024","journal-title":"JCI Insight"},{"key":"R61-20260518","doi-asserted-by":"crossref","first-page":"147\u201376","DOI":"10.1152\/physrev.00048.2019","article-title":"Diversity and biology of cancer-associated fibroblasts","volume":"101","author":"Biffi","year":"2021","journal-title":"Physiol Rev"},{"key":"R62-20260518","doi-asserted-by":"crossref","first-page":"101041","DOI":"10.1016\/j.drup.2023.101041","article-title":"The promising role of tumor-associated macrophages in the treatment of cancer","volume":"73","author":"Wang","year":"2024","journal-title":"Drug Resist Updat"},{"key":"R63-20260518","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1038\/s41698-024-00522-z","article-title":"Targeting M2-like tumor-associated macrophages is a potential therapeutic approach to overcome antitumor drug resistance","volume":"8","author":"Wang","year":"2024","journal-title":"NPJ Precis Oncol"},{"key":"R64-20260518","doi-asserted-by":"crossref","first-page":"e398","DOI":"10.1016\/S1470-2045(20)30107-8","article-title":"Immune checkpoint inhibitor toxicities: systems-based approaches to improve patient care and research","volume":"21","author":"Johnson","year":"2020","journal-title":"Lancet Oncol"},{"key":"R65-20260518","doi-asserted-by":"crossref","first-page":"29\u201338","DOI":"10.1016\/j.coi.2021.02.002","article-title":"Adverse events induced by immune checkpoint inhibitors","volume":"69","author":"Perdigoto","year":"2021","journal-title":"Curr Opin Immunol"},{"key":"R66-20260518","doi-asserted-by":"crossref","first-page":"101370","DOI":"10.1016\/j.beem.2019.101370","article-title":"New insight in endocrine-related adverse events associated to immune checkpoint blockade","volume":"34","author":"Elia","year":"2020","journal-title":"Best Pract Res Clin Endocrinol Metab"},{"key":"R67-20260518","doi-asserted-by":"crossref","first-page":"207\u201313","DOI":"10.2147\/CMAR.S136818","article-title":"Clinical features, diagnostic challenges, and management strategies in checkpoint inhibitor-related pneumonitis","volume":"9","author":"Chuzi","year":"2017","journal-title":"Cancer Manag Res"},{"key":"R68-20260518","doi-asserted-by":"crossref","first-page":"e001731","DOI":"10.1136\/jitc-2020-001731","article-title":"Steroid-refractory PD-(L)1 pneumonitis: incidence, clinical features, treatment, and outcomes","volume":"9","author":"Balaji","year":"2021","journal-title":"J Immunother Cancer"},{"key":"R69-20260518","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1186\/s12890-024-03424-9","article-title":"Immune checkpoint inhibitor-related pneumonitis following discontinuation of pembrolizumab in a patient with advanced lung adenocarcinoma: a case report and literature review","volume":"24","author":"Wang","year":"2024","journal-title":"BMC Pulm Med"},{"key":"R70-20260518","doi-asserted-by":"crossref","first-page":"104591","DOI":"10.1016\/j.critrevonc.2024.104591","article-title":"Recent advances in the study of immune checkpoint inhibitor-associated pneumonia","volume":"206","author":"Feng","year":"2025","journal-title":"Crit Rev Oncol Hematol"},{"key":"R71-20260518","doi-asserted-by":"crossref","first-page":"e005323","DOI":"10.1136\/jitc-2022-005323","article-title":"Single-cell transcriptomics identifies pathogenic T-helper 17.1 cells and pro-inflammatory monocytes in immune checkpoint inhibitor-related pneumonitis","volume":"10","author":"Franken","year":"2022","journal-title":"J Immunother Cancer"},{"key":"R72-20260518","doi-asserted-by":"crossref","first-page":"4305\u201315","DOI":"10.1172\/JCI128654","article-title":"The alveolar immune cell landscape is dysregulated in checkpoint inhibitor pneumonitis","volume":"129","author":"Suresh","year":"2019","journal-title":"J Clin Invest"},{"key":"R73-20260518","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1016\/j.eprac.2024.11.012","article-title":"Prospects and challenges of immunotherapy for thyroid cancer","volume":"31","author":"Song","year":"2024","journal-title":"Endocr Pract"}],"container-title":["International Journal of Surgery"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/JS9.0000000000003301","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,18]],"date-time":"2026-05-18T13:21:52Z","timestamp":1779110512000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/JS9.0000000000003301"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,27]]},"references-count":73,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.1097\/js9.0000000000003301","relation":{},"ISSN":["1743-9159"],"issn-type":[{"value":"1743-9159","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,8,27]]},"assertion":[{"value":"2025-03-17","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-08-13","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}